Clinical significance of serum IL-6 and CRP in multiple myeloma patients
- VernacularTitle:多发性骨髓瘤患者血清I L-6、CR P的临床意义
- Author:
Li-Li JI
1
;
Chen CHEN
;
Xue-Jiao ZHANG
;
Wei-Guang WANG
;
Zhi-Xiang CHENG
;
Ling YUAN
;
Zheng WEI
;
Lu-Ya CHENG
;
Jing-Li ZHUANG
;
Zhi-Mei WANG
;
Feng LI
;
Shan-Hua ZOU
;
Peng LIU
Author Information
1. 复旦大学附属中山医院血液科
- Keywords:
multiple myeloma;
IL-6;
C reactive protein
- From:
Chinese Journal of Clinical Medicine
2016;23(3):337-340
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the relationship between interleukin 6 (IL-6) ,C reactive protein (CRP) and the staging of multiple myeloma (M M ) patients and their role in predicting efficacy .Methods:Serum IL-6 and CRP levels in M M patients admitted to the Department of Hematology ,Zhongshan Hospital Affiliated to Fudan University ,between January 1 , 2015 and January 31 ,2016 were reviewed and the differences of serum IL-6 and CRP levels in MM patients with different DS stages ,ISS stages and chemotherapy efficacy (4 circles) were analyzed .Results:There was no significant difference in serum IL-6 and CRP levels in the patients with different DS stages or ISS stages .There was statistical significance (P< 0 .05) in serum CRP levels in the patients pre-treatment between the high-efficiency group ,the medium-efficiency group ,and the ineffective group .Conclusions:Elevated CRP might indicate poor efficacy of chemotherapy in MM patients ,and IL-6 level is not enough to reflect the status of myeloma IL-6 signaling pathway .
